论文部分内容阅读
目的 关于尿激酶溶栓治疗急性脑梗死的治疗价值分析?方法 选择2018 年1 月至2019 年10 月到我院治疗的68 例急性脑梗死患者随机分为观察组与对照组,每组34 例?两组分别实施尿激酶溶栓和常规治疗,比较效果?结果 观察组(32 例,占94.12%)治疗有效率明显比对照组(24 例,占70.59%)更高,有统计学差异(P 0.05)?治疗以后观察组患者的美国国立卫“,”Objective To analyze the therapeutic value of urokinase thrombolysis in the treatment of acute cerebral infarction. Methods A total of 68 patients with acute cerebral infarction who were treated in our hospital from January 2018 to October 2019 were randomly divided into observation group and control group,with 34 cases in each group. The two groups were treated with urokinase thrombolysis and conventional treatment respectively,and the effects in the two groups were compared. Results The observation group (32 cases,accounting for 94.12%) was significantly more effective than the control group (24 cases,accounting for 70.59%),and there was a statistical difference (P 0.05). The National Institutes of Health Stroke Scale Score (NIHSS) and Activities of Daily Living Score (ADL) were significantly better than the control group,and there was a statistical difference (P <0.05). Conclusion Urokinase thrombolytic therapy for patients with acute cerebral infarction can effectively improve the efficiency of treatment,without serious adverse reactions,and can improve the patients\' neurological function and quality of life. It is worth recommending.